New antiviral therapies for hepatitis C

References

• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 244, 359–362 (1989). Describes the discovery of HCV.
   Google Scholar
• Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J. Viral. Hepat 6, 35–47 (1999).
   PubMedGoogle Scholar
• Alter MJ, Kruszon-Moran D, Nainan OV, et al The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 341, 556–562 (1999).
   PubMed Web of Science ®Google Scholar
• Kim WR. The burden of hepatitis C in the United States. Hepatology 36, S30—S34 (2002).
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology 26, 155-20S (1997).
   Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, et al Treatment of chronic non-A, non-B hepatitis with recombinant human a interferon. A preliminary report. N Engl J. Med 315, 1575–1578 (1986).
   PubMed Web of Science ®Google Scholar
• Chung RT, He W, Saquib A, et al. Hepatitis C virus replication is directly inhibited by IFN-a in a full-length binary expression system. Proc. Nad Acad. Sci. USA 98, 9847–9852 (2001).
   PubMedGoogle Scholar
• Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNAreplication in cell culture. Science 290,1972–1974 (2000).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon-a2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J. Med. 339, 1485–1492 (1998).
   PubMed Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon-a2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N EngL J. Med. 339,1493–1499 (1998).
   PubMed Web of Science ®Google Scholar
• Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J. Hepatol. 25, 591–598 (1996).
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon a2b-plus ribavirin for 48 weeks or for 24 weeks versus interferon-a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 352,1426-1432 (1998).
   Google Scholar
• Fang SH, Hwang LH, Chen DS, Chiang BL. Ribavirin enhancement of hepatitis C virus core antigen-specific Type 1 T-helper cell response correlates with the increased IL-12 level. J. Hepatol. 33, 791–798 (2000).
   PubMed Web of Science ®Google Scholar
• Crotty S, Maag D, Arnold JJ, et al. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 6,1375–1379 (2000).
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon-a2a plus ribavirin for chronic hepatitis C virus infection. N EngL J. Med. 347, 975–982 (2002).
   PubMed Web of Science ®Google Scholar
• ••Pivotal study showing PEG-IFN-u2a withRBV is superior to standard IFN with RBV.
   Google Scholar
• Manns MB McHutchison JG, Gordon SC, et al. Peginterferon-a2b plus ribavirin compared with interferon-a2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Manns M, Patel K, et al International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 123, 1061–1069 (2002).
   PubMed Web of Science ®Google Scholar
• •SVR is improved if patients take over 80% of their IFN and ribavarin, for over 80% of the recommended length of treatment.
   Google Scholar
• McHutchison JG. Novel therapies for HBV and HCV. Clinical care options for Hepatitis Symposium, CA, USA 19–22 June (2003).
   Google Scholar
• Lin CC, Luu T, Lourenco D, et al. Absorption, pharmacokinetics and excretion of levovirin in rats, dogs and cynomolgus monkeys. J. Antimicrob. Chemother. 51, 93–99 (2003).
   PubMedGoogle Scholar
• Yeh LT, Fang JW, Nguyen M, et al. Determination of viramidine/ribavirin in human RBC following single oral dosing of viramidine in a Phase 1 study. Hepatology 34(Suppl.), 345A (2002).
   Google Scholar
• Mangia A, Leandro G, Helbling B, et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: a meta-analysis of individual patient data from 6 clinical trials. Hepatology 34(Suppl.), 570A (2002).
   Google Scholar
• Ideo G, Attili A, Chirianni A, et al. PEG-IFN a2A (401(D) (Pegasys) plus amatadine (AMA) or ribavirin (RBV) in naive patients with chronic hepatitis C (CHC). Hepatology 34(Suppl.), 570A (2002).
   Google Scholar
• Craxi A, Lo Lacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck? j. Hepatol. 35, 527–530 (2001).
   Google Scholar
• Zhou S, Liu R, Baroudy BM, et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310, 333–342 (2003).
   PubMed Web of Science ®Google Scholar
• McHutchison JG, Cheung R, Shiffman ML, et al. A 4 week trial of VX 497 (an IMPDH inhibitor) combined with interferon in previously treated patients with chronic hepatitis C. Hepatology 34(Suppl.), 329A (2002).
   Google Scholar
• Sarobe P, Lasarte JJ, Casares N, et al. Abnormal priming of CD4(+) T-cells by dendritic cells expressing hepatitis C virus core and El proteins. J. Viral. 76, 5062–5070 (2002).
   PubMed Web of Science ®Google Scholar
• Zein NN, Bonefield T, Yen-Lieberman LR, Thomassen MJ. Treatment with soluble tumor necrosis factor-a (TNFa) receptors (Etanercept, Eta) results in a synergistic effect on T-cell reactivity after exposure to pegylated (PEG) interferon (INF). Hepatology 38(Suppl.), 298A (2002).
   Google Scholar
• Zein NN. A Phase II randomized, double-blind, placebo-controlled study of tumor necrosis factor antagonist (Etanercept, Enbrel) as an adjuvant to interferon and ribavirin in naive patients with chronic hepatitis C. Hepatology 26(Suppl.), 304A (2002).
   Google Scholar
• Rasi G, Pierimarchi P, Sinibaldi Vallebona P, et al. Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma. Int. ImmunopharmacoL 3, 1169–1176 (2003).
   PubMed Web of Science ®Google Scholar
• Andreone P, Cursaro C, Gramenzi A, et al. In vitro effect of thymosin-al and interferon-a on Thl and Th2 cytokine synthesis in patients with chronic hepatitis C. J. Viral Hepat. 8, 194–201 (2001).
   PubMed Web of Science ®Google Scholar
• Sherman KE, Sjogren M, Creager RL, et al. Combination therapy with thymosin al and interferon for the treatment of chronic hepatitis C infection: a randomized, placebo-controlled double-blind trial. Hepatology 27, 1128–1135 (1998).
   PubMed Web of Science ®Google Scholar
• Pileri P, Uematsu Y, Campagnoli S, et al. Binding of hepatitis C virus to CD81. Science 282, 938–941 (1998).
   PubMed Web of Science ®Google Scholar
• Agnello V, Abel G, Elfahal M, et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl Acad. Sci. USA 96, 12766–12771 (1999).
   PubMed Web of Science ®Google Scholar
• Bartenschlager R. In vitro models for hepatitis C. Virus Res. 82, 25–32 (2002).
   PubMedGoogle Scholar
• Choo Q-L, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc. Natl Acad. Sci. USA 91, 1294–1298 (1994).
   PubMed Web of Science ®Google Scholar
• Eren R, Ilan E, Nussbaum A, et al. Development and clinical evaluation of human monoclonal antibodies for treating HCV infection. Hepatology 287A (2002).
   PubMedGoogle Scholar
• Nevens F, Roskams T, Van Vlierberghe H, et al. A pilot study of therapeutic vaccination with envelope protein El in 35 patients with chronic hepatitis C. Hepatology 38, 1289–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Lee PA, Blatt LM, Blanchard KS, et al. Pharmacokinetics and tissue distribution of a ribozyme directed against hepatitis C virus RNA following subcutaneous or intravenous administration in mice. Hepatology 32, 640–646 (2000).
   PubMedGoogle Scholar
• Tong M, Schiff E, Jensen DM, et al. Preliminary analysis of a Phase II study of Heptazyme. A nuclease resistant ribozyme targeting Hepatitis C virus (HCV) RNA. Hepatology 34 (Suppl.), 360A (2002).
   Google Scholar
• Witherell GW. ISIS-14803 (Isis Pharmaceuticals). Curr. Opin. Investig. Drugs 2, 1523–1529 (2001).
   PubMedGoogle Scholar
• McHutchinson JG, Pockros PJ, Patel K, et al. A Phase 1B dose escalation trial of Isis 14803, an antisense inhibitor of HCV, in patients with chronic HCV: final report. Hepatology 34(Suppl.), 303A (2002).
   Google Scholar
• Gordon S, Bacon BR, Jacobson IM, et al. A, Phase II, 12-week study of Isis 14803, an antisense inhibitor of HCV for the treatment of chronic Hepatitis C. Hepatology 34(Suppl.), 362A (2002).
   Google Scholar
• Hannon GJ. RNA interference. Nature 418, 244–251 (2002).
   PubMed Web of Science ®Google Scholar
• •Excellent review of siRNA.
   Google Scholar
• Randall G, Grakoui A, Rice CM. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. Proc. Natl Acad Sci. USA 100, 235–240 (2003).
   PubMed Web of Science ®Google Scholar
• Wilson JA, Jayasena S, Kiworova A, et al RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc. Nail Acad Sci. USA 100, 2783–2788 (2003).
   PubMed Web of Science ®Google Scholar
• Sakamoto N, Enomoto N, Maekawa S, et al Inhibition of intracellular hepatitis C virus replication by adenovirus delivery of vector-derived small interfering RNA. Hepatology 38\(Suppl. 1), 222A (2003).
   PubMedGoogle Scholar
• Abid K, Liu R, Rossi C, et al In vitro antiviral activity of SCH6, a novel inhibitor of the hepatitis C virus NS3 serine protease. Hepatology 38\(Suppl. 1), 220A (2003).
   Google Scholar
• Hinrichsen H, Benhamou Y, Reiser M, et al First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 34(Suppl.), 379A (2003).
   Google Scholar
• Lamarre D, Anderson PC, Bailey M, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426, 186–189 (2003).
   PubMed Web of Science ®Google Scholar
• •• In vitro and in vivo data on the serine protease inhibitor BILN 2061.
   Google Scholar
• Benhamou Y, Hinrichsen H, Sentjens R, et al. Safety, tolerability and antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis. Hepatology 34, (Suppl.) 304A (2002).
   Google Scholar
• Reiser M, Hinrichsen H, Benhamou Y, et al. Antiviral effect of BILN 2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, non-genotype 1. Hepatology 38\(Suppl. 1), 221A (2003).
   Google Scholar
• Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300, 1145–1148 (2003).
   PubMed Web of Science ®Google Scholar
• •• Demonstrates that the NS3/4A serine protease inhibits the action of IRF–3.
   Google Scholar
• Ilan E, Arazi J, Nussbaum O, et al. The hepatitis C virus (HCV)-Trimera mouse: a model for evaluation of agents against HCV. J. Infect. Dis. 185,153-161 (2002).
   Google Scholar
• Dafan S, Ilan S, Nussbaum O, et al In vitro and in vivo evaluation of HCV polymerase inhibitors as potential drug candidates for treatment of chronic hepatitis C infection. Hepatology 38\(Suppl. 1) (2003).
   Google Scholar